biote Corp.
For the period ended Dec 31, 2024. Filed Mar 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 14, 2025
BTMD$1.11+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $39,342 | $89,002 |
| Accounts receivable, net | 7,631 | 6,809 |
| Inventory, net | 14,845 | 17,307 |
| Other current assets | 6,309 | 9,225 |
| Total current assets | 68,127 | 122,343 |
| Property and equipment, net | 6,973 | 1,218 |
| Capitalized software, net | 3,877 | 4,973 |
| Goodwill | 5,833 | — |
| Intangible assets, net | 5,500 | — |
| Operating lease right-of-use assets | 3,246 | 1,877 |
| Deferred tax assets, net | 28,742 | 24,884 |
| Other non-current assets | 72 | — |
| Total assets | $122,370 | $155,295 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $5,813 | $4,155 |
| Accrued expenses | 11,293 | 8,497 |
| Term loan, current | 6,250 | 6,250 |
| Deferred revenue, current | 2,961 | 3,002 |
| Earnout liabilities, current | 100 | — |
| Operating lease liabilities, current | 523 | 311 |
| Share repurchase liabilities, current | 24,574 | — |
| Total current liabilities | 51,514 | 22,215 |
| Term loan, net of current portion | 101,199 | 106,630 |
| Deferred revenue, net of current portion | 1,553 | 1,322 |
| Operating lease liabilities, net of current portion | 2,890 | 1,680 |
| Share repurchase liabilities, net of current portion | 44,300 | — |
| Other non-current liability | 1,500 | — |
| TRA liability | 4,479 | 18,894 |
| Earnout liabilities, net of current portion | 17,135 | 41,100 |
| Total liabilities | 224,570 | 191,841 |
| Commitments and contingencies (See Note 20) | ||
| Stockholders’ Deficit | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding as of December 31, 2024 and 2023, respectively | — | — |
| Class A common stock, $0.0001 par value, 600,000,000 shares authorized; 33,073,277 and 35,842,383, shares issued, 31,485,777 and 34,254,883 shares outstanding as of December 31, 2024 and 2023, respectively | 3 | 3 |
| Class V voting stock, $0.0001 par value, 100,000,000 shares authorized; 7,249,879 and 38,819,066 shares issued, 5,221,653 and 28,819,066 shares outstanding as of December 31, 2024 and 2023, respectively | 1 | 3 |
| Additional paid-in capital | — | — |
| Accumulated deficit | (100,297) | (29,391) |
| Accumulated other comprehensive loss | (35) | (12) |
| Treasury stock, at cost | (5,600) | — |
| biote Corp.’s stockholders’ deficit | (105,928) | (29,397) |
| Noncontrolling interest | 3,728 | (7,149) |
| Total stockholders’ deficit | (102,200) | (36,546) |
| Total liabilities and stockholders’ deficit | $122,370 | $155,295 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.